BROMOCRIPTINE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C32H40BrN5O5
Molecular Weight	654.5952
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)C[C@@]1([H])C(=O)N2CCC[C@@]2([H])[C@]3(N1C(=O)[C@](C(C)C)(N=C([C@]4([H])C=C5c6cccc7c6c(C[C@@]5([H])N(C)C4)c(Br)[nH]7)O)O3)O

InChI

InChIKey=OZVBMTJYIDMWIL-AYFBDAFISA-N

InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1

HIDE SMILES / InChI

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf
Curator's Comment:: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf | https://www.drugs.com/mtm/bromocriptine.html

Bromocriptine is an ergot derivative with potent dopamine receptor agonist activity, which activates post-synaptic dopamine receptors. Bromocriptine is indicated for the treatment of dysfunctions associated with hyperprolactinemia. Bromocriptine therapy is indicated in the treatment of acromegaly and in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. It is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Some commonly reported adverse reactions include nausea, fatigue, dizziness, vomiting and headache. Bromocriptine may interact with dopamine antagonists, butyrophenones and certain other agents.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 281 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8787038	Agonist 2456	36.0 nM [Ki]
Dopamine D3 receptor 84 Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8787038	Agonist 2456	197.0 nM [Ki]
Dopamine D1 receptor 94 Target ID: CHEMBL2056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8787038	Agonist 2456	2.2 µM [Ki]
Adrenergic receptor alpha-2 113 Target ID: CHEMBL2093864 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20138024	Activator 1335

Conditions

Condition	Modality	Highest Phase	Product
Parkinson's disease 218 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf	Palliative	Approved 7997	PARLODEL Approved Use Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy. Launch Date 2.67839996E11
Acromegaly 20 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf	Primary	Approved 7997	PARLODEL Approved Use Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy. Launch Date 2.67839996E11
Hyperprolactinemia-associated dysfunctions 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017962s065s068lbl.pdf	Primary	Approved 7997	PARLODEL Approved Use Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate tablets are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine mesylate tablets treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate tablets therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate tablets therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate tablets therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate tablets offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate tablets are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate tablets therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing end of dose failure on levodopa therapy. Bromocriptine mesylate tablets therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (on-off phenomenon). Continued efficacy of bromocriptine mesylate tablets therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate tablets. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine mesylate treated patients than in levodopa/carbidopa treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate tablets therapy. Launch Date 2.67839996E11
Type 2 diabetes mellitus 240 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020866lbl.pdf	Primary	Approved 7997	CYCLOSET Approved Use Drug is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date 1.24139523E12

C_max

Value	Dose	Co-administered	Analyte	Population
628 pg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017962s081lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BROMOCRIPTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
2377 pg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017962s081lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BROMOCRIPTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
4.85 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017962s081lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BROMOCRIPTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
4% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017962s081lbl.pdf	5 mg 1 times / day steady-state, oral dose: 5 mg route of administration: Oral experiment type: STEADY-STATE co-administered:		BROMOCRIPTINE plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
4.8 mg 1 times / day multiple, oral (max) Recommended Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf Page: p.3	unhealthy, 27-80 n = 3070 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 27-80 Sex: M+F Population Size: 3070 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf Page: p.3	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf Page: p.3
4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699	unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699	Disc. AE: Nausea, Dizziness... AEs leading to discontinuation/dose reduction: Nausea (4%) Dizziness (2.8%) Asthenia (1.5%) Rhinitis (1.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699
4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20332352 Page: p.1505, 1507	unhealthy, 59.5 +/- 10.2 n = 2054 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 59.5 +/- 10.2 Sex: M+F Population Size: 2054 Sources: https://pubmed.ncbi.nlm.nih.gov/20332352 Page: p.1505, 1507	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea Sources: https://pubmed.ncbi.nlm.nih.gov/20332352 Page: p.1505, 1507
100 mg 1 times / day multiple, oral Highest studied dose Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2758194 https://www.healthline.com/health/bromocriptine-oral-tablet#about	unhealthy Health Status: unhealthy Condition: Parkinson's Disease Sources: https://pubmed.ncbi.nlm.nih.gov/2758194 https://www.healthline.com/health/bromocriptine-oral-tablet#about	Sources: https://pubmed.ncbi.nlm.nih.gov/2758194 https://www.healthline.com/health/bromocriptine-oral-tablet#about
300 mg single, oral Highest studied dose Dose: 300 mg Route: oral Route: single Dose: 300 mg Sources: https://pubmed.ncbi.nlm.nih.gov/22216518 Page: p.978	unhealthy n = 1 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/22216518 Page: p.978	Sources: https://pubmed.ncbi.nlm.nih.gov/22216518 Page: p.978
30 mg 1 times / day multiple, oral (total) Recommended Dose: 30 mg, 1 times / day Route: oral Route: multiple Dose: 30 mg, 1 times / day Sources: https://www.medicines.org.uk/emc/product/1202/smpc#POSOLOGY	unhealthy Health Status: unhealthy Condition: Prolactinomas\|Hypogonadism\|Galactorrhea syndromes\|Infertility Sources: https://www.medicines.org.uk/emc/product/1202/smpc#POSOLOGY	Sources: https://www.medicines.org.uk/emc/product/1202/smpc#POSOLOGY

AEs

AE	Significance	Dose	Population
Nausea	Disc. AE	4.8 mg 1 times / day multiple, oral (max) Recommended Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf Page: p.3	unhealthy, 27-80 n = 3070 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 27-80 Sex: M+F Population Size: 3070 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020866s006s007lbl.pdf Page: p.3
Asthenia	1.5% Disc. AE	4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699	unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699
Rhinitis	1.5% Disc. AE	4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699	unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699
Dizziness	2.8% Disc. AE	4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699	unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699
Nausea	4% Disc. AE	4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699	unhealthy, 55+/-1 n = 314 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 55+/-1 Sex: M+F Population Size: 314 Sources: https://pubmed.ncbi.nlm.nih.gov/11139820 Page: p.1691, 1699
Nausea	Disc. AE	4.8 mg 1 times / day multiple, oral MTD Dose: 4.8 mg, 1 times / day Route: oral Route: multiple Dose: 4.8 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/20332352 Page: p.1505, 1507	unhealthy, 59.5 +/- 10.2 n = 2054 Health Status: unhealthy Condition: Type 2 diabetes mellitus Age Group: 59.5 +/- 10.2 Sex: M+F Population Size: 2054 Sources: https://pubmed.ncbi.nlm.nih.gov/20332352 Page: p.1505, 1507

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1172 substrate 1470		substrate 1038

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
P-gp 1089	CYP3A 154 CYP2C8 586 CYP2C19 830 CYP4A11 90 OATP1A2 55 OATP2B1 88 P-gp 1223	P-gp 225

Drug as perpetrator

Target	Modality	Activity
CYP3A4 1462	inhibitor 2614 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017962s081lbl.pdf	yes [IC50 1.69 uM]
P-gp 1255	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/11856485/; https://pubmed.ncbi.nlm.nih.gov/9514944/; https://pubmed.ncbi.nlm.nih.gov/18598736/	yes [Ki 6.52 uM]
P-gp 1255	inducer 1333 Sources: https://pubmed.ncbi.nlm.nih.gov/9111066/	yes

Drug as victim

Target	Modality	Activity
CYP2C19 830	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017962s081lbl.pdf Page: 3.0	inconclusive
CYP2C8 586	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/31147443/	likely
CYP2D6 1038	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/31147443/	likely
CYP4A11 90	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/31147443/	likely
CYP3A 154	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/017962s081lbl.pdf Page: 3.0	yes
CYP3A4 1470	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/020866Orig1s000ClinPharmR.pdf Page: 26.0	yes
OATP1A2 55	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/32343897/	yes
OATP2B1 88	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/32343897/	yes
P-gp 1223	substrate 2752 Sources: https://pubmed.ncbi.nlm.nih.gov/16263252/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3181	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3181
ChemicalBook	CB6136426	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6136426
ZINC	ZINC000053683151	http://zinc15.docking.org/substances/ZINC000053683151
eMolecules	1933648	https://www.emolecules.com/cgi-bin/more?vid=1933648
eMolecules	36518002	https://www.emolecules.com/cgi-bin/more?vid=36518002

PubMed

Title	Date	PubMed
Cardiovascular responses to intrathecal dopamine receptor agonists in conscious DOCA-salt hypertensive rats.	1999	10626749
Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.	1999 Nov	10591873
[The treatment of cyclic mastalgia--a comparative study between the preparations Bromocriptine and Geritamin].	2000	10826333
Sleep attacks and Parkinson's disease treatment.	2000 Apr 15	10776750
Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders.	2000 Dec	11194712
[Dopaminergic agonists in the treatment of Parkinson's disease].	2000 Dec	11194495
Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.	2000 Dec	11145192
Clinical pharmacology of dopamine agonists.	2000 Jan	10641988
Role of dopamine D3 receptors in thermoregulation: a reappraisal.	2000 Jan 17	10683862
Neuroleptic malignant syndrome after venlafaxine.	2000 Jan 22	10675082
Clinical features and medical treatment of male prolactinomas.	2001	11482696
Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.	2001	11279721
Dopamine D2 receptor gene expression in human adenohypophysial adenomas.	2001 Apr	11444429
Mechanisms of inverse agonism of antipsychotic drugs at the D(2) dopamine receptor: use of a mutant D(2) dopamine receptor that adopts the activated conformation.	2001 Apr	11299312
In vivo and in vitro effects of prolactin and growth hormone on lipid metabolism in a teleost, Anabas testudineus (Bloch).	2001 Apr	11290458
Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances.	2001 Apr 17	11383385
Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism.	2001 Apr 27	11392629
Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats.	2001 Aug	11473532
Luteolytic effect of prolactin is dependent on the degree of differentiation of luteal cells in the rat.	2001 Aug	11466211
Upregulation of lymphocyte apoptosis as a strategy for preventing and treating autoimmune disorders: a role for whole-food vegan diets, fish oil and dopamine agonists.	2001 Aug	11461185
Bromocriptine-induced dissociation of hyperglycemia and prolactin response to restraint.	2001 Feb	11267627
Pituitary adenomas in childhood and adolescence. Clinical analysis of 10 cases.	2001 Feb	11263478
[Decreased tumor size in hypophyseal macroadenoma--empty sella syndrome].	2001 Feb 15	11256227
Mechanisms for suckling-induced changes in expression of prolactin receptor in the hypothalamus of the lactating rat.	2001 Feb 9	11164823
Maternal prolactin secretion during labor. The role of dopamine.	2001 Jan	11167186
Characterization of acute inhibition of Na/H exchanger NHE-3 by dopamine in opossum kidney cells.	2001 Jan	11135072
Pharmacology of [3H]R(+)-7-OH-DPAT binding in the rat caudate-putamen.	2001 Jan	10913686
Hepatic Encephalopathy.	2001 Jul	11467622
Centrally mediated effects of bromocriptine on cardiac sympathovagal balance.	2001 Jul	11463772
Rehabilitative management of post-stroke visuospatial inattention.	2001 Jul 10	11400902
Microvessel density in pituitary adenomas and carcinomas.	2001 Jun	11469692
Effect of serotonin depletion by p-chlorophenylalanine on serum prolactin levels in estrogen-treated ovariectomized rats: insights concerning the serotoninergic, dopaminergic and opioid systems.	2001 Jun	11456281
[Pharmacological effects of cabergoline against parkinsonism].	2001 Jun	11436517
Neuroleptic malignant syndrome during a change from haloperidol to risperidone.	2001 Jun	11408988
Estrogen, prolactin, and autoimmunity: actions and interactions.	2001 Jun	11407318
Cerebrospinal fluid fistula as the presenting manifestation of pituitary adenoma: case report with a 4-year follow-up.	2001 Jun	11400039
The effect of prolactin and bromocriptine on human peripheral immune status.	2001 Mar	11314742
Positive outcomes in traumatic brain injury-vegetative state: patients treated with bromocriptine.	2001 Mar	11245751
Effects of chronic bromocriptine treatment on tyrosine hydroxylase (TH) mRNA expression, TH activity and median eminence dopamine concentrations in ageing rats.	2001 Mar	11207940
[Parkinson disease: diagnostic and therapeutic criteria].	2001 Mar 3	11268897
Haloperidol-stomach lesions attenuation by pentadecapeptide BPC 157, omeprazole, bromocriptine, but not atropine, lansoprazole, pantoprazole, ranitidine, cimetidine and misoprostol in mice.	2001 Mar 9	11292068
Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats.	2001 May	11393583
Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice.	2001 May	11303052
Fertile estrus induced in bitches by bromocryptine, a dopamine agonist: a clinical trial.	2001 May 1	11393217
[Reversible blindness caused by an invasive prolactinoma].	2001 May 25	11413749
[Cerebral meningeal hemorrhage and acute cerebral angiopathy associated with the taking of phenylpropanolamine: a new case].	2001 May-Jun	11475816
Sleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study.	2001 May-Jun	11391132
Dopamine D(2) receptor activation causes mitogenesis via p44/42 mitogen-activated protein kinase in opossum kidney cells.	2001 Sep	11518777
Clinical management of neuroleptic malignant syndrome.	2001 Winter	11525080

Patents

Sample Use Guides

In Vivo Use Guide

Type 2 diabetes mellitus: Initial dose is one tablet (0.8 mg) daily increased weekly by one tablet until maximal tolerated daily dose of 1.6 to 4.8 mg is achieved. Hyperprolactinemic Indications: The initial dosage in adults is ½ to one 2½ mg scored tablet daily. An additional 2½ mg tablet may be added to the treatment regimen as tolerated every 2-7 days until an optimal therapeutic response is achieved. The therapeutic dosage ranged from 2.5-15 mg daily in adults studied clinically. Parkinson’s Disease: The initial dose is ½ of a 2½ mg twice daily with meals. Assessments are advised at 2-week intervals during dosage titration to ensure that the lowest dosage producing an optimal therapeutic response is not exceeded. If necessary, the dosage may be increased every 14-28 days by 2½ mg/day with meals.

Route of Administration: Oral

In Vitro Use Guide

Bromocriptine has been shown to augment glutamate uptake at a concentration of 10 uM in HeLaS3 cells that stably express EAAT1, the human homolog of GLAST. Therefore, it was evaluated whether bromocriptine affects D-[3 H]aspartate uptake in HEK293/EcR cells expressing EAAT2. However, bromocriptine failed to alter D-[3 H]aspartate uptake at concentrations as high as 30 uM, suggesting that bromocriptine has little or no effect on the excitatory amino acid uptake via EAAT2.

Name

Type

Language

BROMOCRIPTINE

Official Name

English

SANDOZ 15-754

Code

English

2-BROMO-.ALPHA.-ERGOCRYPTINE

Common Name

English

BROMOCRIPTINE [USAN]

Common Name

English

ERGOTAMAN-3',6',18-TRIONE, 2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)-, (5'.ALPHA.)-

Common Name

English

ERGOCRYPTINE, 2-BROMO-

Common Name

English

BROMOCRIPTINE [MI]

Common Name

English

BROMOCRIPTINE [VANDF]

Common Name

English

BROMOCRIPTINE [INN]

Common Name

English

BROMOCRIPTINE [WHO-DD]

Common Name

English

(+)-BROMOCRIPTINE

Systematic Name

English

BROMERGOCRYPTINE

Common Name

English

Classification Tree Code System Code

LIVERTOX

123